Cencora (COR)
Cencora (COR)
One-line summary: One of the "Big Three" US drug wholesalers (formerly AmerisourceBergen); franchises Good Neighbor Pharmacy, 4,000+ independent community pharmacy owners — the same channel-survival lead as mckesson, and subject to the same unverified beneficiary link.
What it is
Cencora (NYSE: COR) is a pharmaceutical distributor and healthcare solutions company, one of the Big Three alongside mckesson and Cardinal Health. It franchises Good Neighbor Pharmacy — "more than 4,000 community pharmacy owners" as of July 2025 — and operates the Elevate Provider Network for Part D network access.
Why it matters to stock-market
Same chain as mckesson: state NADAC + dispensing-fee floors (state-nadac-floor-reimbursement-mandates) prohibit below-acquisition-cost reimbursement in the commercial market, which should decelerate independent-pharmacy closures and stabilize the franchise channel where wholesaler sell-side margin is structurally best (~98% of WAC to independents vs ~94% to large chains).
⚠ Also same caveat: the terminal link is unverified, and Cencora's counter-evidence is arguably worse than McKesson's — see below.
Key facts
All from 2026-07-17-autoresearch-pbm-pass-through-preemption-profit-pool-migration.
- Good Neighbor Pharmacy: "more than 4,000 community pharmacy owners" as of July 2025 (Cencora).
- The margin asymmetry (Drug Channels): wholesalers earn their thinnest sell-side discounts — best margin — on small pharmacies (~98% of WAC) vs large chains (~94% of WAC), while PBM reimbursements average "96% of WAC or lower."
- ⚠ Part D network position is the worst of the group: Cencora's Elevate members "will not be preferred in any major plan for 2026" — a ninth consecutive year (Drug Channels, 2026-02).
- The strategic pivot away from distribution: the Big Three have spent over $16 billion since 2013 on physician-practice MSOs because distribution is thin-margin and clinical services are "higher-margin... reducing dependency on distribution spreads" (Drug Channels, 2025-10).
Weaknesses (from a thesis-input perspective)
- ⚠ The beneficiary link is an unverified inferential leap — the autoresearch flags it explicitly: no source quantifies wholesaler earnings sensitivity to independent-pharmacy count; no COR management commentary in the past 30 days connects state NADAC floors to outlook. "Do not emit a signal on Chain B without sizing this."
- Nine consecutive years of Elevate Part D non-preferred status is a structural channel problem that state commercial-market floors do not fix.
- Cencora's own $16B MSO strategy points away from retail distribution.
- No independent-franchise economics are disclosed at a level that would let anyone size this.
Open questions
- What is COR's earnings sensitivity to independent-pharmacy count? Unquantified — the gating question.
- Does the commercial-market NADAC floor offset nine years of Part D network erosion, or are they simply different books?